Biotransformation of Chrysin to Baicalein: Selective C6-Hydroxylation of 5,7-Dihydroxyflavone Using Whole Yeast Cells Stably Expressing Human CYP1A1 Enzyme by Williams, Ibidapo S. et al.
Subscriber access provided by INDIAN INST OF INTEGRATIVE MED JAMMU
Journal of Agricultural and Food Chemistry is published by the American Chemical
Society. 1155 Sixteenth Street N.W., Washington, DC 20036
Published by American Chemical Society. Copyright © American Chemical Society.
However, no copyright claim is made to original U.S. Government works, or works
produced by employees of any Commonwealth realm Crown government in the course
of their duties.
Article
Biotransformation of chrysin to baicalein: Selective C6-
hydroxylation of 5,7-dihydroxyflavone using whole
yeast cells stably expressing human CYP1A1 enzyme
Ibidapo S Williams, Shifali Chib, Vijay Nuthakki, Linda Gatchie, Prashant Joshi, Niteen
Narkhede, Ram A. Vishwakarma, Sandip B. Bharate, Saurabh Saran, and Bhabatosh Chaudhuri
J. Agric. Food Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jafc.7b02690 • Publication Date (Web): 07 Aug 2017
Downloaded from http://pubs.acs.org on August 8, 2017
Just Accepted
“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted
online prior to technical editing, formatting for publication and author proofing. The American Chemical
Society provides “Just Accepted” as a free service to the research community to expedite the
dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts
appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been
fully peer reviewed, but should not be considered the official version of record. They are accessible to all
readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered
to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published
in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just
Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor
changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers
and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors
or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
 1
 1 
Biotransformation of chrysin to baicalein: Selective C6-2 
hydroxylation of 5,7-dihydroxyflavone using whole yeast 3 
cells stably expressing human CYP1A1 enzyme 4 
Ibidapo S. Williams,
†,‡,#
 Shifali Chib,
§,#
 Vijay Nuthakki,⊥
#
 Linda Gatchie,
†,‡ 
Prashant Joshi, ⊥ Niteen A. 5 
Narkhede,
ǁ
 Ram A. Vishwakarma,⊥
 
Sandip B. Bharate,⊥
,φ,* 
Saurabh Saran,
§,
* Bhabatosh Chaudhuri*
,†,‡
 6 
# Contributed equally to this work as a first author. 7 
†
Leicester School of Pharmacy, De Montfort University, Leicester, LE1 9BH, UK 8 
‡
CYP Design Limited, Innovation Centre, 49 Oxford Street, Leicester, LE1 5XY, UK 9 
§
Fermentation Technology  Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, 10 
Jammu-180001, India. 11 
⊥Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-12 
180001, India 13 
ǁ
 Instrumentation Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu-180001, 14 
India 15 
 φ
Academy of Scientific & Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, 16 
Canal Road, Jammu-180001, India 17 
 18 
19 
Page 1 of 25
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
 2
 20 
ABSTRACT:  21 
Naturally occurring polyphenolic compounds are of medicinal importance because of their unique 22 
antioxidant, anticancer and chemopreventive properties. Baicalein, a naturally occurring polyhydroxy 23 
flavonoid possessing a diverse range of pharmacological activities, has been used in traditional 24 
medicines for treatment of various ailments. Apart from its isolation from natural sources, its synthesis 25 
has been reported via multi-step chemical approaches. Here we report a preparative-scale 26 
biotransformation, using whole yeast cells stably expressing human cytochrome P450 1A1 (CYP1A1) 27 
enzyme, that allows regioselective C6-hydroxylation of 5,7-dihydroxyflavone (chrysin) to form 5,6,7-28 
trihydroxyflavone (baicalein). Molecular modelling reveals why chrysin undergoes such specific 29 
hydroxylation mediated by CYP1A1. More than 92% reaction completion was obtained using a shake-30 
flask based process that mimics fed-batch fermentation. Such highly efficient selective hydroxylation, 31 
using recombinant yeast cells, has not been reported earlier. Similar CYP-expressing yeast cell-based 32 
systems are likely to have wider applications in the syntheses of medicinally important polyphenolic 33 
compounds. 34 
 35 
Keywords: Biotransformation, chrysin, baicalein, CYP1A1, yeast cells, hydroxylation 36 
 37 
38 
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INTRODUCTION 39 
Baicalein (5,6,7-trihydroxyflavone) (1) was originally isolated from the roots of Scutellaria baicalensis 40 
(Chinese skullcap) which is used for treatment of chronic hepatitis, inflammatory diseases, tumors, and 41 
diarrhea in China, Korea, Taiwan, and Japan.
1
 Its isolation has also been reported from another plant, 42 
Oroxylum indicum (Indian trumpet flower).
2
 Baicalein is known for its anticancer properties in various 43 
cancer types
2-22
 including pancreatic, gastric and colorectal cancers, multiple myeloma, head and neck 44 
cancer, and breast cancer.
23, 24
 Baicalein is also considered as an anti-inflammatory
25, 26
 that generally 45 
protects against oxidative stress,
27
 more specifically in cardiac cells,
28
 and in cisplatin-induced acute 46 
kidney injury.
29
 Because of its wide-ranging medicinal applications, an industrial scale protocol for its 47 
production would be considered as important.  48 
Baicalein has primarily been produced via five approaches: (a) single-step hydrolysis of the natural 49 
product baicalin, a glycoside,
30
 (b) 4-step total synthesis from a cinnamic acid derivative,
31
 (c) 4-step 50 
total synthesis from 3,4,5-trimethoxyphenol,
32
 (d) 3-step total synthesis from 2,4,5,6-51 
tetrahydroxyacetophenone,
33
 and (e) 6-step synthesis from chrysin
34
 involving methylation, bromination, 52 
acylation, nucleophilic replacement of Br with OMe, followed by de-acylation and demethylation as key 53 
steps. 54 
Selective transformation, using efficient biocatalysts, of a low value phytochemical to high value 55 
phytochemical is an exciting area of bioorganic chemistry. Sordon and coworkers
35
 have reported 56 
biotransformations of natural flavonoids naringenin, hesperetin, chrysin, apigenin, luteolin, quercetin, 57 
epicatechin, and biochanin A using the natural yeast, Rhodotorula glutinis.  This approach produced 58 
norwogonin (5,7,8-trihydroxyflavone) from chrysin (5,7-dihydroxyflavone). Here we report a 59 
preparative scale process for biotransformation of chrysin to baicalein, via selective C6-hydroxylation 60 
using recombinant human cytochrome P450-1A1 (CYP1A1) enzyme expressed within baker’s yeast 61 
(Saccharomyces cerevisiae) cells. This is the first single-step protocol for a high-yield conversion of 62 
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chrysin to baicalein and, therefore, may serve as a simple and cheap strategy for production of baicalein 63 
in an industrial scale. 64 
MATERIALS AND METHODS 65 
General. All chemicals were obtained from Sigma-Aldrich and were used as received. 
1
H NMR spectra 66 
were recorded on Brucker-Avance DPX FT-NMR 400 MHz instrument. Chemical data for protons are 67 
reported in parts per million (ppm) downfield from tetramethylsilane and are referenced to the residual 68 
proton in the NMR solvent (CD3OD, 3.31 ppm). ESI-MS were recorded on Waters QTOF mass 69 
spectrometer.  70 
HPLC analysis was performed on Shimadzu LC-6AD system connected with C18 column (4.6 x 25 mm, 71 
5 µ). Mobile phase consisted of 0.1% formic acid (A) and methanol (B) using isocratic elution (30: 70 – 72 
A: B). Flow rate was 1 mL/min and detection wavelength was 270 nm. 73 
LC-MS analysis was performed on Waters Acquity UPLC system. The column used was C18, 1.7 µ 74 
with dimensions of 100 x 2.1 mm (column temp. 30 °C). Binary gradient system was used. Mobile 75 
phase A consisted of 5% acetonitrile in water (with 0.1% formic acid). Mobile phase B consisted of 76 
acetonitrile with 0.1% formic acid. Gradient details are: Time in min (% B concentration): 0.01 (10), 77 
0.25 (10), 9.00 (100), 10.00 (100), 11.00 (10), 12.00 (10). PDA range: 220 nm to 400 nm; flow rate: 0.3 78 
mL/min. 79 
Biotransformation experiment. Yeast strains, each of which contain two copies of human CYP1A1 or 80 
CYP1A2 genes, downstream of the ADH2 promoter, integrated into chromosomal loci of the genome of 81 
the yeast strain W303-1a (ATCC 208352), were used for biotransformation (Section S2 of supporting 82 
information). Expressed CYP1A1 and CYP1A2 proteins were confirmed by Western blotting 83 
(supporting information-S4). The strains, from frozen stocks, were revived in 250 mL Erlenmeyer 84 
baffled flasks containing 50 mL YPD (Yeast, Peptone, Dextrose) medium with composition (g/L): 85 
peptone 20; yeast extract 10; glucose 15.0, pH 6.0. The flasks were shaken at 200 rpm, at 28 °C. Three 86 
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consecutive YPD pre-cultures were grown for high biomass production, before addition of the substrate 87 
to cells grown in SD (Synthetic Defined) medium. Typically, loopful of CYP-containing freshly grown 88 
yeast cells was inoculated in a 500 mL Erlenmeyer baffled flask separately containing 100 mL YPD 89 
medium (pre-culture -1) at 28 °C for 24 h. The cells were harvested after 24 h and inoculated into a new 90 
500 mL baffled flask containing 100 mL YPD medium (pre-culture -2) at 30 °C for 18 h. The process 91 
was repeated three times for the cells to reach an OD600, of ~90. 92 
The harvested cells, ~3.0 mL (OD600, ~90), were inoculated in 50 mL of minimal SD medium contained 93 
in a 1 L baffled flask. Composition of SD medium (g/L): dextrose 1.0; dipotassium phosphate 7.0; 94 
monopotassium phosphate 2.0; sodium citrate 0.50; magnesium sulphate 0.10; ammonium sulphate 1.0, 95 
pH 7.0 ± 0.2 at 28 °C. Initially, reaction was carried out with 0.2 mg/mL of chrysin. Later, the chrysin at 96 
different concentrations viz. 0.2, 1, 2, 5 and 10 mg/mL were incubated in 50 mL of SD medium (DMSO 97 
was used for initial dissolution of the compound, and keeping the DMSO concentration < 0.5% in final 98 
reaction medium) for 72 h at 28 °C, 200 rpm. After every 24 h, the medium was replenished with 1.5% 99 
w/v of glucose. For optimization of incubation time, the SD cell culture media were harvested after 24, 100 
48, 72, 96, 120, 144 and 160 h, and were then analysed on TLC and HPLC/ LC-MS to monitor the 101 
yields of biotransformation at each time point. 102 
Isolation and characterization of baicalein. The reaction media was extracted with ethyl acetate (3 103 
times). The combined ethyl acetate layer was concentrated on vacuo-rotavapor to obtain crude extracts 104 
that contained the biotransformation product. The crude residue was loaded on a reverse phase (C18) 105 
silica gel column packed in water. The crude extract was loaded on the column by making a slurry with 106 
C18 silica gel mesh 200-400 (Sigma-Aldrich, product no. 377635). The column was then eluted with 107 
increasing concentrations of methanol in water. The desired product was collected at 50% methanol in 108 
water. Evaporation of the solvent gave a yellow solid which was characterized as baicalein (1). Yellow 109 
powder; m.p. 262-265 °C (Lit. 264-265 °C); TLC: Rf = 0.5 (3% methanol in DCM) and 0.8 (40% 110 
EtOAc: hexane with 0.1% acetic acid); 
1
H NMR (CD3OD, 400 MHz, δ ppm): 7.91 (dd, J = 4.0, 8.0 Hz, 111 
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2H), 7.48 (m, 3H), 6.66 (s, 1H), 6.55 (s, 1H); ESI-MS: m/z 271.10 [M+H]
+
. The spectral data was 112 
identical to that reported in the literature
32
 and TLC matched with reference sample obtained from 113 
Sigma-Aldrich (CAS number 491-67-8). 114 
Molecular modeling: The docking of chrysin with CYP1A1 (PDB ID: 4I8V) was performed using 115 
GLIDE module of Schrodinger molecular modeling software, using the protocols as described in our 116 
earlier publications.
36, 37
 The docking protocol was validated by docking known ligand α-117 
naphthoflavone (ANF). The interaction pattern of docked ANF and ligand from co-crystallized protein 118 
(4I8V) are shown in the supporting information (Section S8). 119 
RESULTS AND DISCUSSION 120 
CYP enzymes are known for their exceptional ability to carry out hydroxylation, epoxidation or 121 
demethylation reactions in a regioselective fashion, both in plants and humans. It is essential for human 122 
CYP450 enzymes to be integrated on the endoplasmic reticular (ER) membranes to manifest its native 123 
activity. Baker’s yeast cells possess ER membranes which are not present in prokaryotic E. coli cells. 124 
Eukaryotic baker’s yeast cells were chosen because they can grow as rapidly as bacterial cells and they 125 
are as amenable as bacteria for scale-up in fermentors. Using Baker's yeast cells, we have developed an 126 
efficient technology for stable expression of human CYP enzymes within these cells. Using this 127 
platform, recombinant baker’s yeast cells can continue to express CYPs in shake flasks, over a week or 128 
more, with increasing activities, under conditions that mimic fed-batch growth (Supporting Information; 129 
S1). Microsomal CYP enzymes, isolated from these same recombinant yeast cells, have successfully 130 
been used by us earlier as drug discovery tools for screening synthetic compounds and natural product 131 
repositories to identify possible cancer chemopreventive agents.
37-39
  132 
Selection of CYPs for biotransformation of chrysin. In this work, use of recombinant CYP-133 
expressing whole yeast cells has been explored for their ability to be used as biocatalysts for 134 
biotransformation reactions. For this purpose, we chose the flavonoid chrysin as a substrate. As the 135 
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cytochrome P450 family 1 enzymes CYP1A1 and CYP1A2 are reported to oxidize dietary flavonoids,
40-
136 
42
 herein we chose two yeast-expressed enzymes of the CYP1 sub-family (i.e. CYP1A1 and CYP1A2) 137 
as biocatalysts. 138 
Two recombinant yeast strains, each containing two chromosomally integrated copies of CYP1A1 and 139 
CYP1A2 genes under the control of the ethanol-inducible alcohol dehydrogenase 2 (ADH2) promoter, 140 
were created to enable stable and reproducible biotransformation reactions (plasmid maps shown in 141 
Supporting Information, S2). The ADH2 promoter is repressed in the presence of glucose. The aim was 142 
that recombinant yeast cells, containing stably integrated CYP expression cassettes, would be grown 143 
initially in complete YPD medium (containing 2% glucose) to obtain large optical density, measured at a 144 
wavelength of 600 nm (OD600) of ~90, in shake flasks. This would occur without any plasmid loss and 145 
would be achieved over 3 days through repetitive replenishment of glucose, every 24 h, in the non-146 
selective highly nutritious YPD medium. Cells grown in YPD (Figure 1a) would then be re-suspended 147 
in minimal selective SD medium (pH 7.0), supplemented with 1.5% of glucose, for the 148 
biotransformation reaction. It was thought that rich full YPD medium may not be appropriate for 149 
biotransformation since there is a possibility of substrate binding to its ingredients.  150 
For initial optimization, reactions were performed in SD with 10 mg of chrysin in baffled flasks shaking 151 
at 200 rpm for 72 h, at 28 °C (Figure 1b). After every 24 h, the medium was replenished with fresh 152 
glucose to a final concentration of 1.5%. Glucose was exhausted after 12 h of growth of yeast cells when 153 
it was converted to ethanol. Hence, the ethanol-inducible ADH2 promoter was fully induced every 12 h 154 
before more glucose was added to the medium for further rounds of expression.  155 
Figure 1. 156 
The reaction media at each time point was extracted with ethyl acetate. The extracts were analyzed by 157 
TLC followed by HPLC/ LC-MS. The formation of new product on TLC with lower Rf value than the 158 
substrate gave us an indication of a hydroxylation reaction (Supporting Information, S3). LC-MS 159 
Page 7 of 25
ACS Paragon Plus Environment
Journal of Agricultural and Food Chemistry
 8
analysis of the reaction mixture confirmed the product as mono-hydroxy chrysin with mass of m/z 270. 160 
The same product was formed using both the enzymes, CYP1A1 and CYP1A2, expressed within yeast 161 
cells. However, conversion of substrate to product was better with CYP1A1. Therefore, for subsequent 162 
scale-up experiments, only CYP1A1-expressing yeast cells were used for biotransformation.  163 
Scale up and optimization of biotransformation reaction. Scale-up was performed as above; cells 164 
were at first cultivated in non-selective YPD media for 72 h, with fresh glucose (2%) being added every 165 
24 h. Cells were re-suspended in selective SD minimal medium. Chrysin at different concentrations viz. 166 
0.2, 1, 2, 5 and 10 mg/mL were dissolved in DMSO and further incubated in 50 mL of SD medium 167 
(keeping the DMSO concentration < 0.5%) for 72 h at 28 °C, 200 rpm. The chrysin-containing cell 168 
culture media were replenished with glucose every 24 h to a final concentration of 1.5%. The reaction 169 
using chrysin at concentration of 2 mg/mL (100 mg of chrysin) was observed to be the most efficient. 170 
With 5 and 10 mg/mL concentrations, incomplete biotransformation occurred, probably because the 171 
small number of cells, used for growth in these specific experiments, was inhibited by the substrate.  172 
Based on these results, it was decided to optimize the time period for biotransformation. For this, we 173 
chose 2 mg/mL concentration of substrate with reaction time points of 24, 48, 72, 96, 120, 144 and 160 174 
h. HPLC analyses of the reaction mixture after 24, 48, 72, 96, 120, 144 and 160 h incubations indicated 175 
that, at 144 h, there was nearly complete conversion (>92%) of chrysin to the product. The HPLC 176 
chromatograms of reaction mixtures at representative four time intervals are shown in Figure 2. In 177 
HPLC analysis, the concentration of sample injected at each time interval was kept constant. The 178 
increase in the AUC of baicalein with increase in the time, from 24 h to 144 h, is indicative of the fact 179 
that the highest amount of baicalein is formed at the 144 h time point.  180 
Figure 2 181 
The relative percentages (AUC) of chrysin and baicalein at different time intervals are depicted in Figure 182 
3. As shown in Figure 3, the percentage conversion of chrysin to baicalein increased with time. 183 
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Similarly, Figure 3b shows increased peak height (mAU) of baicalein with increase in reaction time. 184 
Figures 3a and 3b, in combination, indicate that 144 h is the optimal reaction time for this 185 
transformation. Further details of HPLC analysis are provided in supporting information, section S5. 186 
Figure  3. 187 
Isolation and characterization of baicalein. Initial isolation attempts using normal phase silica gel 188 
column chromatography showed significant loss in the product yield. Therefore, we attempted reverse 189 
phase C18 silica gel column chromatography where water-methanol was used as the mobile phase. The 190 
product was isolated at 50% methanol in water and was characterized by spectral analysis and by 191 
comparison of its TLC with reference sample.  192 
The 
1
H NMR of chrysin contains a typical bunch of three singlets at chemical shift values in the range of 193 
6 to 7 ppm. These three singlets at δ 6.24, 6.49 and 6.74 ppm correspond to the protons present at C6, 194 
C8 and C3 positions. The C6-proton appears with an up-field shift in comparison to two other aromatic 195 
protons at C3 and C-6, because of the shielding effect from two adjacent C5 and C7 hydroxyls. It is 196 
obvious that the hydroxylation reaction is possible, either on A or C ring. Since there was no change in 197 
the chemical shift value pattern of C ring (δ 7.91, dd, 2H and δ 7.48, m, 3H), it would indicate that the 198 
C-ring is intact and no hydroxylation had taken place on this ring. The hydroxylation on A ring has two 199 
possibilities, either C6- or C8 hydroxylation. Hydroxylation at C6-position will form baicalein (5,6,7-200 
trihydroxyflavone) whereas hydroxylation at C8-position will form norwogonin (5,7,8-201 
trihydroxyflavone) as a product. It was interesting to see that, in the 
1
H NMR of the obtained product, 202 
the up-field singlet (δ 6.24 ppm) disappeared. This singlet peak in chrysin corresponds to the proton 203 
present at C6-position. This gave us a clear indication that hydroxylation occurred at the C6-position, 204 
which means that the product is 5,6,7-trihydroxyflavone. This is the naturally occurring flavone, 205 
commonly named as ‘baicalein’. Furthermore, on comparison of the 
1
H NMR of the obtained product 206 
with norwogonin,
35
 the possibility of norwogonin as the product was ruled out. In literature, the 207 
biotransformation of chrysin using natural yeast, Rhodotorula glutinis yielded C-8 hydroxylated product 208 
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norwogonin,
35
   however in the present study, C-6 hydroxylated product (baicalein) was formed, which 209 
may be possibly because of the regio-specificity of the CYP1A1 enzyme. 210 
Mass analysis of the isolated product showed m/z peak at 271 in ES+ve mode, which matched with the 211 
predicted product. The final confirmation of the assigned product was done by co-TLC and HPLC 212 
analysis with the reference standard of baicalein (CAS number: 491-67-8)’ purchased from Sigma-213 
Aldrich. TLC images as well as HPLC analysis clearly matched the reference standard (TLC images are 214 
shown in Supporting Information -S3). 215 
The LC-MS analysis was also performed for the extract as well as isolated baicalein (Figure 4). 216 
Figure 4. 217 
Docking of chrysin with CYP1A1. In order to decipher the rationale for regioselective hydroxylation, 218 
chrysin was docked with the substrate binding site of CYP1A1 enzyme (PDB ID: 4I8V). The interaction 219 
pattern of chrysin with CYP1A1 is depicted in Figure 5. It is interesting to note that the A-ring of 220 
chrysin orients towards the heme. Furthermore, the C-6 carbon of A-ring is present in close-proximity 221 
with heme protein, suggesting that the reactive heme-oxo intermediate should possibly form at this 222 
position. Other key interactions which help in stabilizing this orientation of chrysin includes: (a) 223 
hydrophobic π-π interactions of Phe-224 of I-helix with B and C rings; (b) π-π interactions of Phe-123 224 
with A ring; and (c) polar H-bonding of C-7 hydroxyl group with Ser-122. This observed orientation, 225 
excludes the possibility of hydroxylation at C-8 and at aromatic CH of B and C rings. 226 
Figure 5. 227 
Our efforts using yeast whole cells have resulted in the development of a reproducible preparative-scale 228 
biotransformation process for the conversion of chrysin to baicalein (5,6,7-trihydroxyflavone). 229 
According to the literature, the medicinal effects of baicalein are more profound than that of chrysin. 230 
Furthermore, commercially available baicalein is at least 60-times more expensive than chrysin. Thus, 231 
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this protocol described here can be utilized for production of a high value phytochemical from a low 232 
value one, using a simple, low-cost, one-step biotransformation reaction. 233 
In conclusion, we have demonstrated the ability of whole yeast cells, that overexpress the human 234 
CYP1A1 enzyme, to catalyse biotransformation of >92% of the natural flavonoid chrysin to baicalein. 235 
Optimal aeration, neutral pH and maintenance of glucose concentration, throughout the reaction, played 236 
very important roles in the biotransformation reaction. The example demonstrated in this paper, 237 
provides an opportunity for further exploring the utility of stable recombinant CYP enzyme-expressing 238 
yeast cells for industrial production of medicinally important polyphenolic compounds.  239 
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FIGURE LEGENDS 
 
Figure 1. (a) CYP1A1-expressing cells grown in YPD Medium in test-tubes; (b) Biotransformation 
reaction using CYP1A1 in SD medium in shake-flasks; (c) scheme showing conversion of chrysin to 
baicalein, and their key 
1
H NMR chemical shift values  
Figure 2. HPLC analysis of biotransformation reaction at different time intervals. (a) HPLC 
chromatogram of chrysin reference standard; (b) HPLC chromatogram of baicalein reference standard; 
(c) HPLC chromatogram of biotransformation reaction after 24 hrs of incubation time; (d) HPLC 
chromatogram of biotransformation reaction after 48 hrs of incubation time; (e) HPLC chromatogram of 
biotransformation reaction after 96 hrs of incubation time; (f) HPLC chromatogram of biotransformation 
reaction after 144 hrs of incubation time. The concentration of sample injected is kept constant at each 
time interval; therefore an increase in AUC (and peak height) with the increase in incubation time 
indicates progress of the reaction. 
Figure 3. (a) Relative percentage  (±SD) of chrysin and baicalein at different time intervals during a 
typical biotransformation reaction (the percentages are based on the AUC of the peaks in HPLC analysis 
at 270 nm). (b) Baicalein (tR = 5.99 min) peak height (±SD) at different time intervals during 
biotransformation reaction. 
Figure 4. LC-MS analysis of reaction mixture at 144 h. (a) LC chromatogram of reaction mixture after 
144 h of incubation. (B) LC chromatogram of isolated product; (c) Mass spectra of peak at tR 4.69 min. 
Figure 5. Molecular docking of chrysin with CYP1A1 (PDB: 4I8V), showing the predicted site of 
hydroxylation as C6. 
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